Hepatitis B virus and renal transplantation

Transplantation Reviews

Volumn 25, Issue 3, 2011, Pages 102-109

  Kalia, Harmit ^a   Fabrizi, Fabrizio ^b   Martin, Paul ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; CYCLOSPORIN; ENTECAVIR; GLUCOCORTICOID; HEPATITIS B VACCINE; LAMIVUDINE; RECOMBINANT ALPHA INTERFERON; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ACUTE GRAFT REJECTION; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG EFFICACY; FOLLOW UP; HEMODIALYSIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; INFECTION RISK; KIDNEY TRANSPLANTATION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER DISEASE; MULTICENTER STUDY (TOPIC); PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 79959495777     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2011.02.001     Document Type: Article

References (94)

1. Fabrizi F., Martin P. Management of hepatitis B and C virus infection before and after renal transplantation. Current Opin Organ Transplant 2006, 11:583-588.
2. Fabrizi F., Lunghi G., Poordad F., Martin P. Management of hepatitis B after renal transplantation: an update. J Nephrol 2002, 15:113-122.
3. Fabrizi F., Bunnapradist S., Martin P. Handbook of kidney transplantation 2004, 334-338. 4th ed. G. Danovitch (Ed.).
4. Aroldi A., Tarantino A., Montagnino G., et al. Renal transplant recipients and chronic liver disease: statistical evaluation of predisposing factors. Nephron 1992, 61:290-292.
5. Bang B.K., Yang C.W., Yoon S.A., Kim Y.S., Yoon Y.S., Koh Y.B. Prevalence and clinical course of hepatitis B and hepatitis C liver disease in cyclosporine-treated renal allograft recipients. Nephron 1995, 70:397-401.
6. Fornairon S., Pol S., Legendre C., et al. The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. Transplantation 1996, 62:297-299.
7. Pouteil-Noble C., Tardy J.C., Chossegros P., et al. Co-infection by hepatitis B virus and hepatitis C virus in renal transplantation: morbidity and mortality in 1098 patients. Nephrol Dial Transplant 1995, 10:122-124.
8. Hiesse C., Buffet C., Neyrat N., et al. Impact of HBs antigenemia on long-term patient survival and causes of death after renal transplantation. Clin Transplant 1992, 46:461-467.
9. Ingsathit A., Thakkinstian A., Kantachuvesiri S., Sumethkul V. Different impacts of hepatitis B virus and hepatitis C virus on the outcome of kidney transplantation. Transplant Proc 2007, 39:1424-1428.
10. Mathurin P., Mouquet C., Poynard T., et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999, 29:257-263.
11. Snyder J.J., Israni A.K., Peng Y., Zhang L., Simon T.A., Kasiske B.L. Rates of first infection following kidney transplant in the United States. Kidney Int 2009, 75:317-326.
12. Fabrizi F., Bunnapradist S., Martin P. HBV infection in patients with end-stage renal disease. Semin Liver Dis 2004, 24(Suppl. 1):63-70.
13. Pirson Y., Alexandre G.P., Ypersele C. Long-term effect of HBs antigenemia on patient survival after renal transplantation. N Engl J Med 1977, 296:194-196.
14. Berne T.V., Fitzgibbons T.J., Silberman H. The effect of hepatitis B antigenemia on long-term success and hepatic disease in renal allograft recipients. Transplantation 1977, 24:412-415.
15. Hillis W.D., Hillis A., Walker G. Hepatitis B surface antigenemia in renal transplant recipients. JAMA 1979, 242:329-332.
16. Flagg G.L., Silberman H., Takamoto S.K., Berne T. The influence of hepatitis B infection on the outcome of renal allotransplantation. Transplant Proc 1987, 19:2155-2158.
17. Morales J.M., Dominguez-Gil B., Sanz-Guajardo D., Fernandez J., Escuin F. The influence of hepatitis B and hepatitis C virus infection in the recipient on late renal allograft failure. Nephrol Dial Transplant 2004, 19(Suppl. 3):iii72-iii76.
18. Yuan C.H., Liu Y.F., Li G.C. Influence of hepatitis B and hepatitis C virus infection on the outcome of kidney transplantation. Chin Med Sci J 2005, 20:129-132.
19. Breitenfeldt M.K., Rasenack J., Berthold H., et al. Impact of hepatitis B and C on graft loss and mortality after kidney transplantation. Clin Transplant 2002, 16:130-136.
20. Aroldi A., Lampertico P., Montagnino G., et al. Natural history of hepatitis B and C in renal allograft recipients. Transplantation 2005, 79:1132-1136.
21. Ahn H.J., Kim M.S., Kim Y.S., et al. Clinical outcome of renal transplantation in patients with positive pre-transplant hepatitis B surface antigen. J Med Virol 2007, 79:1655-1663.
22. Fabrizi F., Martin P., Dixit V., Kanwal F., Dulai G. HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant 2005, 5:2913-2921.
23. LaQuaglia M.P., Tolkoff-Rubin N.E., Dienstag J.L., et al. Impact of hepatitis on renal transplantation. Transplantation 1981, 32:504-507.
24. Chen J.B., Hsieh H., Hsu K.T., Chen C.H. Impact of donor hepatitis B antigenemia on renal allograft in hepatitis B recipients. Transplant Proc 1996, 28:1490-1492.
25. Rao K.V., Kasiske B.L., Anderson W.R. Variability in the morphological spectrum and clinical outcome of chronic liver disease in hepatitis B-positive and B-negative renal transplant recipients. Transplantation 1991, 51:391-396.
26. Parfrey P.S., Forbes R.D., Hutchinson T.A., et al. The impact of renal transplantation on the course of hepatitis B liver disease. Transplantation 1985, 39:610-615.
27. Matos C.A., Perez R.M., Lemos L.B., et al. Factors associated with the intensity of liver fibrosis in renal transplant patients with hepatitis B virus infection. Eur J Gastroenterol Hepatol 2007, 19:653-657.
28. Farza H., Salmon A.M., Hadchouel M., et al. Hepatitis B surface antigen gene expression is regulated by sex steroids and glucocorticoids in transgenic mice. Proc Natl Acad Sci USA 1987, 84:1187-1191.
29. Tur-Kaspa R., Burk R.D., Shaul Y., Shafritz D.A. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci USA 1986, 83:1627-1631.
30. McMillan J.S., Shaw T., Angus P.W., Locarnini S.A. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology 1995, 22:36-43.
31. Flores P.A., Vierling J.M. Modifications of immunosuppression in hepatitis B virus infection. Curr Opin Organ Transplant 2001, 6:331-337.
32. Dusheiko G., Song E., Bowyer S., et al. Natural history of hepatitis B virus infection in renal transplant recipients-a fifteen-year follow-up. Hepatology 1983, 3:330-336.
33. Nagington J., Cossart Y.E., Cohen B.J. Reactivation of hepatitis B after transplantation operations. Lancet 1977, I:558-560.
34. Hoofnagle J.H. Reactivation of hepatitis B. Hepatology 2009, 49(Suppl. 5):S156-S165.
35. Berger A., Preiser W., Kachel H.G., Sturmer M., Doerr H.W. HBV reactivation after kidney transplantation. J Clin Virol 2005, 32:162-165.
36. Savas N., Colak T., Yilmaz U., Emiroglu R., Haberal M. Hepatitis B virus reactivation after renal transplantation: report of two cases. Transplant Int 2007, 20:301-304.
37. Grotz W., Rasenack J., Benzing T., et al. Occurrence and management of hepatitis B virus reactivation following kidney transplantation. Clin Nephrol 1998, 49:385-388.
38. Savas N., Colak T., Selcuk H., Yilmaz U., Haberal M. Clinical course of hepatitis B virus infection in renal allograft recipients. Dig Dis Sci 2007, 52:3440-3443.
39. Yen T.H., Huang C.C., Lin H.H., et al. Does hepatitis C virus affect the reactivation of hepatitis B following renal transplantation?. Nephrol Dial Transplant 2006, 21:1046-1052.
40. Murakami R., Amada N., Sato T., et al. Reactivation of hepatitis and lamivudine therapy in 11 HBsAg-positive renal allograft recipients: a single-center experience. Clin Transplant 2006, 20:351-358.
41. Wu W., Chen Y., Ruan B., Li J.I. Gene heterogeneity of hepatitis B virus isolates from patients with severe hepatitis B. Hepatobiliary Pancreat Dis Int 2005, 4:530-534.
42. Tsai M.C., Chen C.H., Lee C.M., et al. The role of HBV genotype, core promoter and precore mutations in advanced liver disease in renal transplant recipients. J Hepatol 2009, 50:281-288.
43. Reinke P., Baginski S., Gunther S., Kruger D.H., Will H., Meisel H. Association between the accumulation of hepatitis B virus core gene deletion mutants and progression of liver disease in long-term renal transplant recipients. Transplant Proc 1997, 29:815-816.
44. Preikschat P., Gunther S., Reinhold S., et al. Complex HBV populations with mutations in core promoter, C gene, and pre-S region associated with development of cirrhosis in long-term renal transplant recipients. Hepatology 2002, 35:466-477.
45. Bock C.T., Buerke B., Tillmann H.L., et al. Relevance of hepatitis B core gene deletions in patients after kidney transplantation. Gastroenterology 2003, 124:1809-1820.
46. Lu M., Lorentz T. De novo infection in a renal transplant recipient caused by novel mutants of hepatitis B virus despite the presence of protective anti-hepatitis B surface antibody. J Infect Dis 2003, 187:1323-1326.
47. Vajdic C.M., McDonald S.P., McCredie M.R., et al. Cancer incidence before and after renal transplantation. JAMA 2006, 296:2823-2831.
48. Chiang Y.J., Wang H.H., Liu K.L., Chu S.H., Lee W.C. Hepatocellular carcinoma following renal transplantation: experience in northern Taiwan. Transplant Proc 2008, 40:2397-2399.
49. Saeian K., Franco J., Komorowski R.A., Adams M.B. Hepatocellular carcinoma after renal transplantation in the absence of cirrhosis or viral hepatitis: a case series. Liver Transplant Surg 1999, 5:46-49.
50. Chiang Y.J., Chen C.H., Wu C.T., et al. De novo cancer occurrence after renal transplantation: a medical center experience in Taiwan. Transplant Proc 2004, 36:2150-2151.
51. Fan W.C., King K.L., Loong C.C., Wu C.W. Hepatocellular carcinoma after renal transplantation: the long-term impact of cirrhosis on chronic hepatitis B virus infection. Transplant Proc 2006, 38:2080-2083.
52. Tang S., Lo C.M., Chan T.M., Lai K.N. Early detection of hepatocellular carcinoma in hepatitis B-positive renal transplant recipients. J Surg Oncol 1999, 72:99-101.
53. Chok K.S., Lam C.M., Li F.K., et al. Management of hepatocellular carcinoma in renal transplant recipients. J Surg Oncol 2004, 87:99-101.
54. Cheng S.B., Yeh D.C., Shu K.H., et al. Liver resection for hepatocellular carcinoma in patients who have undergone prior renal transplantation. J Surg Oncol 2006, 93:273-278.
55. Chuang C.H., Chien Y.S., Cheng Y.T., Hu T.H., Hsieh H. Hepatocellular carcinoma in renal transplant recipients. Transplant Proc 2008, 40:2392-2394.
56. Ridruejo E., Mando O.G., Davalos M., Diaz C., Vilches A. Hepatocellular carcinoma in renal transplant patients. Transplant Proc 2005, 37:2086-2088.
57. Rangel M., Coronado V.G., Euler G.L., Strikas R. Vaccine recommendations for patients on chronic dialysis. Semin Dial 2000, 13:101-107.
58. Da Roza G., Loewen A., Djurdjev O., et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis 2003, 42:1184-1192.
59. Tsouchnikas I., Dounousi E., Xanthopoulou K., Papakonstantinou S., Thomoglu V., Tsakiris D. Loss of hepatitis B immunity in hemodialysis patients acquired either naturally or after vaccination. Clin Nephrol 2007, 68:228-234.
60. Kong N.C., Beran J., Kee S.A., et al. A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kidney Int 2008, 73:856-862.
61. De Feo T.M., Grossi P., Poli F., et al. Kidney transplantation from anti-HBc positive donors: results from a retrospective Italian study. Transplantation 2006, 81:71-80.
62. Natov S.N., Pereira B.J. Transmission of viral hepatitis by kidney transplantation: donor evaluation and transplant policies (part 1: hepatitis B virus). Transplant Infect Dis 2002, 4:117-123.
63. Chan P.C., Lok A.S., Cheng I.K., Chan M.K. The impact of donor and recipient hepatitis B surface antigen status on liver disease and survival in renal transplant recipients. Transplantation 1992, 53:128-131.
64. Veroux M., Puliatti C., Macarone M., et al. Kidney transplantation from hepatitis B surface antigen positive donors into hepatitis B surface antigen positive recipients. Transplant Proc 2005, 37:2467-2468.
65. Veroux P., Veroux M., Sparacino V., et al. Kidney transplantation from donors with viral B and C hepatitis. Transplant Proc 2006, 38:996-998.
66. Berber I., Aydin C., Yigit B., Turkmen F., Titiz I.M., Altaca G. The effect of HBsAg positivity of kidney donors on long-term patient and graft outcome. Transplant Proc 2005, 37:4173-4175.
67. Wei H.K., Loong C.C., King K.L., Wu C.W., Lui W.Y. HBsAg (+) donor as a kidney transplantation deceased donor. Transplant Proc 2008, 40:2097-2099.
68. Sumethkul V., Ingsathit A., Jirasiritham S. Ten-year follow-up of kidney transplantation from hepatitis B surface antigen-positive donors. Transplant Proc 2009, 41:213-215.
69. Jiang H., Wu J., Zhang X., et al. Kidney transplantation from hepatitis B surface antigen positive donors into hepatitis B surface antibody positive recipients: a prospective nonrandomized controlled study from a single center. Am J Transplant 2009, 9:1853-1858.
70. Akalin E., Ames S., Sehgal V., Murphy B., Bromberg J.S. Safety of using hepatitis B virus core antibody or surface antigen-positive donors in kidney or pancreas transplantation. Clin Transplant 2005, 19:364-366.
71. Grotz W., Gondolf K., Rasenack J., Berthold H., Rump L.C., Schollmeyer P. Imminent liver failure in a hepatitis B positive renal allograft recipient: successful therapy with interferon-alpha. Nephrol Dial Transplant 1995, 10:1932-1934.
72. Post A.B., Hricik D.E., Sterling R.K., Bartucci M.R., Jacobs G.H., Schulak J.A. Resolution of hepatitis B viremia in a renal transplant recipient treated with alpha-2b interferon. Nephron 1998, 79:469-471.
73. Durlik M., Gaciong Z., Rowinska D., et al. Long-term results of treatment of chronic hepatitis B, C, and D with interferon alpha in renal allograft recipients. Transpl Int 1998, 11(Suppl. 1):S135-S139.
74. Rostaing L., Modesto A., Baron E., Cisterne J.M., Chabannier M.H., Durand D. Acute renal failure in kidney transplant patients treated with interferon alpha2b for chronic hepatitis C. Nephron 1996, 74:512-516.
75. Ozgur O., Boyacioglu S., Telatar H., Haberal M. Recombinant alpha-interferon in renal allograft recipients with chronic hepatitis C. Nephrol Dial Transplant 1995, 10:2104-2106.
76. Fabrizi F., Martin P., Bunnapradist S., Villa M., Rusconi E., Messa P.G. Lamivudine in the treatment of HBV-related liver disease after renal transplantation: an update. Int J Artif Organs 2005, 28:211-221.
77. Fabrizi F., Dulai G., Dixit V., Bunnapradist S., Martin P. Lamivudine for the treatment of hepatitis B-virus related liver disease after renal transplantation: meta-analysis of clinical trials. Transplantation 2004, 77:859-864.
78. Zubkin M., Balakirev E., Chervinko V., et al. Treatment of chronic hepatitis B with lamivudine in renal transplant recipients. Int J Artif Organs 2007, 30:308-314.
79. Santos F.R.L., Haiashi A.R., Araujo M.R.T., Abensur H., Romao Junior J.E., Noronha I.L. Lamivudine therapy for hepatitis B in renal transplantation. Braz J Med Biol Res 2002, 35:199-203.
80. Kamar N., Sandres-Saune K., Ribes D., et al. Effects of long-term lamivudine therapy in renal transplant recipients. J Clin Virol 2004, 31:298-303.
81. Thabut D., Thibaut V., Bernard-Chabert B., et al. Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B. Eur J Gastroenterol Hepatol 2004, 16:1367-1373.
82. Viganò M., Colombo M., Aroldi A., Lunghi G., Manenti E., Ponticelli C. Long-term lamivudine monotherapy in renal transplant recipients with hepatitis B-related cirrhosis. Antivir Ther 2005, 10:709-713.
83. De Silva H.J., Herath C.A., Sheriff M.H.R. Lamivudine therapy for hepatitis B infection in postrenal transplant patients: results after 36 months follow-up. Liver Int 2005, 25:1074-1075.
84. Chan T.M., Fang G.X., Tang C.S.O., Cheng I.K., Lai K.N., Ho S.K. Pre-emptive lamivudine therapy based on HBV DNA level in HBsAg positive kidney allograft recipients. Hepatology 2002, 36:1246-1252.
85. Han D.J., Kim T.H., Park S.K., et al. Results on pre-emptive or prophylactic treatment of lamivudine in HBsAg (+) renal allograft recipients: comparison with salvage treatment after hepatic dysfunction with HBV recurrence. Transplantation 2001, 71:387-394.
86. Filik L., Karakayali H., Moray G., et al. Lamivudine therapy in kidney allograft recipients who are seropositive for hepatitis B surface antigen. Transplant Proc 2006, 38:496-498.
87. Gwak G.Y., Huh W., Lee D.H., et al. The incidence and clinical outcome of YMDD mutants in hepatitis B surface antigen-positive renal allograft recipients after prolonged lamivudine therapy. Transplant Proc 2007, 39:3121-3126.
88. Fontaine H., Vallet-Pichard A., Chaix M.L., et al. Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. Transplantation 2005, 80:1086-1092.
89. Garcia A., Mazuecos A., Gonzales P., et al. Treatment with adefovir dipivoxil in a renal transplant patient with renal insufficiency and lamivudine-resistant hepatitis B infection. Transplant Proc 2005, 37:1462-1463.
90. De Silva H.J., Dassanayake A.S., Manamperi A., de Silva A.P. Treatment of lamivudine-resistant hepatitis B infection in post-renal transplant patients with adefovir dipivoxil: preliminary results. Transplant Proc 2006, 38:3118-3120.
91. Izzedine H., Kheder-Elfekih R., Housset P., Sarkozy C., Brocheriou I., Deray G. Adefovir dipivoxil-induced acute tubular necrosis and Fanconi syndrome in a renal transplant patient. AIDS 2009, 23:544-545.
92. Kamar N., Huart A., Tack I., Alric L., Izopet J., Rostaing L. Renal side-effects of adefovir in hepatitis B virus (HBV)-positive kidney allograft recipients. Clin Nephrol 2009, 71:36-42.
93. Kamar N., Milioto O., Alric L., et al. Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients. Transplantation 2008, 86:611-614.
94. Marzano A., Angelucci E., Andreone P., for the Italian Association for the Study of the Liver (AISF), et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liv Diseases 2007, 39:397-408.